DIA study links more oversight to better orphan drug access

07/30/2013 | PharmExec.com

A study sponsored by DIA found that countries with more regulatory structures for advancing treatments for rare diseases have greater access by patients to orphan drugs compared with countries with less extensive regulatory frameworks. The U.S. did not do as well as France, Spain, the U.K. and Germany in providing access to 13 orphan treatments, according to the study.

View Full Article in:

PharmExec.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA